APO Research
Talk to an analyst

APO RESEARCH · REPORT

Mirabegron Sustained-release Tablets

Compare research editions
View pricing & licenses

Selected research

Industry Research

Mirabegron Sustained-release Tablets Industry Research Report 2026

27 December 2025123 pages

Choose your research edition.

Industry ResearchMirabegron Sustained-release Tablets Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Mirabegron Sustained-release Tablets Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Mirabegron Sustained-release Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mirabegron Sustained-release Tablets Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Mirabegron Sustained-release Tablets Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Mirabegron Sustained-release Tablets market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Mirabegron Sustained-release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Mirabegron Sustained-release Tablets is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Mirabegron Sustained-release Tablets is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Mirabegron Sustained-release Tablets include Alkem Laboratories, Astellas Pharma, Lupin Pharmaceuticals, Zydus Lifesciences, China Resources Pharmaceutical, Jiangsu Huayang Pharmaceutical, Jiangxi Shanxiang Pharmaceutical, Qilu Pharmaceutical and Shenzhen Main Luck Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Mirabegron Sustained-release Tablets market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Mirabegron Sustained-release Tablets Market by Company

Alkem Laboratories

Astellas Pharma

Lupin Pharmaceuticals

Zydus Lifesciences

China Resources Pharmaceutical

Jiangsu Huayang Pharmaceutical

Jiangxi Shanxiang Pharmaceutical

Qilu Pharmaceutical

Shenzhen Main Luck Pharmaceuticals

CSPC Pharmaceutical

Sichuan Gowell Pharmaceutical

Zhejiang Huayi Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Mirabegron Sustained-release Tablets Segment by Type

25mg per Tablet

50mg per Tablet

Mirabegron Sustained-release Tablets Segment by Application

Hospital and Clinic

Pharmacy

Other

Mirabegron Sustained-release Tablets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mirabegron Sustained-release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mirabegron Sustained-release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mirabegron Sustained-release Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Mirabegron Sustained-release Tablets manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Mirabegron Sustained-release Tablets by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Mirabegron Sustained-release Tablets in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Mirabegron Sustained-release Tablets Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Mirabegron Sustained-release Tablets Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Mirabegron Sustained-release Tablets Sales Market Share by Manufacturers (2021-2026) Table 8. Global Mirabegron Sustained-release Tablets Revenue of Manufacturers (2021-2026) Table 9. Global Mirabegron Sustained-release Tablets Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Mirabegron Sustained-release Tablets Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Mirabegron Sustained-release Tablets Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Mirabegron Sustained-release Tablets, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Mirabegron Sustained-release Tablets, Product Type & Application Table 14. Global Mirabegron Sustained-release Tablets Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Mirabegron Sustained-release Tablets by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Alkem Laboratories Company Information Table 19. Alkem Laboratories Business Overview Table 20. Alkem Laboratories Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Alkem Laboratories Mirabegron Sustained-release Tablets Product Portfolio Table 22. Alkem Laboratories Recent Developments Table 23. Astellas Pharma Company Information Table 24. Astellas Pharma Business Overview Table 25. Astellas Pharma Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Astellas Pharma Mirabegron Sustained-release Tablets Product Portfolio Table 27. Astellas Pharma Recent Developments Table 28. Lupin Pharmaceuticals Company Information Table 29. Lupin Pharmaceuticals Business Overview Table 30. Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio Table 32. Lupin Pharmaceuticals Recent Developments Table 33. Zydus Lifesciences Company Information Table 34. Zydus Lifesciences Business Overview Table 35. Zydus Lifesciences Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Zydus Lifesciences Mirabegron Sustained-release Tablets Product Portfolio Table 37. Zydus Lifesciences Recent Developments Table 38. China Resources Pharmaceutical Company Information Table 39. China Resources Pharmaceutical Business Overview Table 40. China Resources Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. China Resources Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 42. China Resources Pharmaceutical Recent Developments Table 43. Jiangsu Huayang Pharmaceutical Company Information Table 44. Jiangsu Huayang Pharmaceutical Business Overview Table 45. Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 47. Jiangsu Huayang Pharmaceutical Recent Developments Table 48. Jiangxi Shanxiang Pharmaceutical Company Information Table 49. Jiangxi Shanxiang Pharmaceutical Business Overview Table 50. Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 52. Jiangxi Shanxiang Pharmaceutical Recent Developments Table 53. Qilu Pharmaceutical Company Information Table 54. Qilu Pharmaceutical Business Overview Table 55. Qilu Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Qilu Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 57. Qilu Pharmaceutical Recent Developments Table 58. Shenzhen Main Luck Pharmaceuticals Company Information Table 59. Shenzhen Main Luck Pharmaceuticals Business Overview Table 60. Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio Table 62. Shenzhen Main Luck Pharmaceuticals Recent Developments Table 63. CSPC Pharmaceutical Company Information Table 64. CSPC Pharmaceutical Business Overview Table 65. CSPC Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. CSPC Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 67. CSPC Pharmaceutical Recent Developments Table 68. Sichuan Gowell Pharmaceutical Company Information Table 69. Sichuan Gowell Pharmaceutical Business Overview Table 70. Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 72. Sichuan Gowell Pharmaceutical Recent Developments Table 73. Zhejiang Huayi Pharmaceutical Company Information Table 74. Zhejiang Huayi Pharmaceutical Business Overview Table 75. Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 77. Zhejiang Huayi Pharmaceutical Recent Developments Table 78. Chia Tai Tianqing Pharmaceutical Company Information Table 79. Chia Tai Tianqing Pharmaceutical Business Overview Table 80. Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 82. Chia Tai Tianqing Pharmaceutical Recent Developments Table 83. Global Mirabegron Sustained-release Tablets Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 84. Global Mirabegron Sustained-release Tablets Sales by Region (2021-2026) & (K Units) Table 85. Global Mirabegron Sustained-release Tablets Sales Market Share by Region (2021-2026) Table 86. Global Mirabegron Sustained-release Tablets Sales by Region (2027-2032) & (K Units) Table 87. Global Mirabegron Sustained-release Tablets Sales Market Share by Region (2027-2032) Table 88. Global Mirabegron Sustained-release Tablets Revenue by Region (2021-2026) & (US$ Million) Table 89. Global Mirabegron Sustained-release Tablets Revenue Market Share by Region (2021-2026) Table 90. Global Mirabegron Sustained-release Tablets Revenue by Region (2027-2032) & (US$ Million) Table 91. Global Mirabegron Sustained-release Tablets Revenue Market Share by Region (2027-2032) Table 92. North America Mirabegron Sustained-release Tablets Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. North America Mirabegron Sustained-release Tablets Sales by Country (2021-2026) & (K Units) Table 94. North America Mirabegron Sustained-release Tablets Sales by Country (2027-2032) & (K Units) Table 95. North America Mirabegron Sustained-release Tablets Revenue by Country (2021-2026) & (US$ Million) Table 96. North America Mirabegron Sustained-release Tablets Revenue by Country (2027-2032) & (US$ Million) Table 97. Europe Mirabegron Sustained-release Tablets Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Europe Mirabegron Sustained-release Tablets Sales by Country (2021-2026) & (K Units) Table 99. Europe Mirabegron Sustained-release Tablets Sales by Country (2027-2032) & (K Units) Table 100. Europe Mirabegron Sustained-release Tablets Revenue by Country (2021-2026) & (US$ Million) Table 101. Europe Mirabegron Sustained-release Tablets Revenue by Country (2027-2032) & (US$ Million) Table 102. Asia Pacific Mirabegron Sustained-release Tablets Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Asia Pacific Mirabegron Sustained-release Tablets Sales by Country (2021-2026) & (K Units) Table 104. Asia Pacific Mirabegron Sustained-release Tablets Sales by Country (2027-2032) & (K Units) Table 105. Asia Pacific Mirabegron Sustained-release Tablets Revenue by Country (2021-2026) & (US$ Million) Table 106. Asia Pacific Mirabegron Sustained-release Tablets Revenue by Country (2027-2032) & (US$ Million) Table 107. South America Mirabegron Sustained-release Tablets Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. South America Mirabegron Sustained-release Tablets Sales by Country (2021-2026) & (K Units) Table 109. South America Mirabegron Sustained-release Tablets Sales by Country (2027-2032) & (K Units) Table 110. South America Mirabegron Sustained-release Tablets Revenue by Country (2021-2026) & (US$ Million) Table 111. South America Mirabegron Sustained-release Tablets Revenue by Country (2027-2032) & (US$ Million) Table 112. Middle East and Africa Mirabegron Sustained-release Tablets Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Middle East and Africa Mirabegron Sustained-release Tablets Sales by Country (2021-2026) & (K Units) Table 114. Middle East and Africa Mirabegron Sustained-release Tablets Sales by Country (2027-2032) & (K Units) Table 115. Middle East and Africa Mirabegron Sustained-release Tablets Revenue by Country (2021-2026) & (US$ Million) Table 116. Middle East and Africa Mirabegron Sustained-release Tablets Revenue by Country (2027-2032) & (US$ Million) Table 117. Global Mirabegron Sustained-release Tablets Sales by Type (2021-2026) & (K Units) Table 118. Global Mirabegron Sustained-release Tablets Sales by Type (2027-2032) & (K Units) Table 119. Global Mirabegron Sustained-release Tablets Sales Market Share by Type (2021-2026) Table 120. Global Mirabegron Sustained-release Tablets Sales Market Share by Type (2027-2032) Table 121. Global Mirabegron Sustained-release Tablets Revenue by Type (2021-2026) & (US$ Million) Table 122. Global Mirabegron Sustained-release Tablets Revenue by Type (2027-2032) & (US$ Million) Table 123. Global Mirabegron Sustained-release Tablets Revenue Market Share by Type (2021-2026) Table 124. Global Mirabegron Sustained-release Tablets Revenue Market Share by Type (2027-2032) Table 125. Global Mirabegron Sustained-release Tablets Price by Type (2021-2026) & (US$/Unit) Table 126. Global Mirabegron Sustained-release Tablets Price by Type (2027-2032) & (US$/Unit) Table 127. Global Mirabegron Sustained-release Tablets Sales by Application (2021-2026) & (K Units) Table 128. Global Mirabegron Sustained-release Tablets Sales by Application (2027-2032) & (K Units) Table 129. Global Mirabegron Sustained-release Tablets Sales Market Share by Application (2021-2026) Table 130. Global Mirabegron Sustained-release Tablets Sales Market Share by Application (2027-2032) Table 131. Global Mirabegron Sustained-release Tablets Revenue by Application (2021-2026) & (US$ Million) Table 132. Global Mirabegron Sustained-release Tablets Revenue by Application (2027-2032) & (US$ Million) Table 133. Global Mirabegron Sustained-release Tablets Revenue Market Share by Application (2021-2026) Table 134. Global Mirabegron Sustained-release Tablets Revenue Market Share by Application (2027-2032) Table 135. Global Mirabegron Sustained-release Tablets Price by Application (2021-2026) & (US$/Unit) Table 136. Global Mirabegron Sustained-release Tablets Price by Application (2027-2032) & (US$/Unit) Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Mirabegron Sustained-release Tablets Distributors List Table 140. Mirabegron Sustained-release Tablets Customers List Table 141. Mirabegron Sustained-release Tablets Industry Trends Table 142. Mirabegron Sustained-release Tablets Industry Drivers Table 143. Mirabegron Sustained-release Tablets Industry Restraints Table 144. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Mirabegron Sustained-release Tablets Product Image Figure 5. Global Mirabegron Sustained-release Tablets Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Mirabegron Sustained-release Tablets Market Size (2021-2032) & (US$ Million) Figure 7. Global Mirabegron Sustained-release Tablets Sales (2021-2032) & (K Units) Figure 8. Global Mirabegron Sustained-release Tablets Average Price (US$/Unit) & (2021-2032) Figure 9. 25mg per Tablet Product Image Figure 10. 50mg per Tablet Product Image Figure 11. Hospital and Clinic Product Image Figure 12. Pharmacy Product Image Figure 13. Other Product Image Figure 14. Global Mirabegron Sustained-release Tablets Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Mirabegron Sustained-release Tablets, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Mirabegron Sustained-release Tablets Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Mirabegron Sustained-release Tablets Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Mirabegron Sustained-release Tablets Sales by Region in 2025 Figure 20. Global Mirabegron Sustained-release Tablets Revenue by Region in 2025 Figure 21. North America Mirabegron Sustained-release Tablets Market Size by Country in 2025 Figure 22. North America Mirabegron Sustained-release Tablets Sales Market Share by Country (2021-2032) Figure 23. North America Mirabegron Sustained-release Tablets Revenue Market Share by Country (2021-2032) Figure 24. United States Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Mirabegron Sustained-release Tablets Market Size by Country in 2025 Figure 28. Europe Mirabegron Sustained-release Tablets Sales Market Share by Country (2021-2032) Figure 29. Europe Mirabegron Sustained-release Tablets Revenue Market Share by Country (2021-2032) Figure 30. Germany Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Mirabegron Sustained-release Tablets Market Size by Country in 2025 Figure 41. Asia Pacific Mirabegron Sustained-release Tablets Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Mirabegron Sustained-release Tablets Revenue Market Share by Country (2021-2032) Figure 43. China Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Mirabegron Sustained-release Tablets Market Size by Country in 2025 Figure 52. South America Mirabegron Sustained-release Tablets Sales Market Share by Country (2021-2032) Figure 53. South America Mirabegron Sustained-release Tablets Revenue Market Share by Country (2021-2032) Figure 54. Brazil Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Mirabegron Sustained-release Tablets Market Size by Country in 2025 Figure 58. Middle East and Africa Mirabegron Sustained-release Tablets Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Mirabegron Sustained-release Tablets Revenue Market Share by Country (2021-2032) Figure 60. Egypt Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Mirabegron Sustained-release Tablets Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Mirabegron Sustained-release Tablets Sales Market Share by Type (2021-2032) Figure 66. Global Mirabegron Sustained-release Tablets Revenue Market Share by Type (2021-2032) Figure 67. Global Mirabegron Sustained-release Tablets Price (US$/Unit) by Type (2021-2032) Figure 68. Global Mirabegron Sustained-release Tablets Sales Market Share by Application (2021-2032) Figure 69. Global Mirabegron Sustained-release Tablets Revenue Market Share by Application (2021-2032) Figure 70. Global Mirabegron Sustained-release Tablets Price (US$/Unit) by Application (2021-2032) Figure 71. Mirabegron Sustained-release Tablets Value Chain Figure 72. Mirabegron Sustained-release Tablets Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Mirabegron Sustained-release Tablets Industry Opportunities and Challenges

Scope & coverage.

Types
  • 25mg per Tablet
  • 50mg per Tablet
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Alkem Laboratories
  • Astellas Pharma
  • Lupin Pharmaceuticals
  • Zydus Lifesciences
  • China Resources Pharmaceutical
  • Jiangsu Huayang Pharmaceutical
  • Jiangxi Shanxiang Pharmaceutical
  • Qilu Pharmaceutical
  • Shenzhen Main Luck Pharmaceuticals
  • CSPC Pharmaceutical
  • Sichuan Gowell Pharmaceutical
  • Zhejiang Huayi Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Mirabegron Sustained-release Tablets Market Size (2021-2032)
  4. 2.2.2 Global Mirabegron Sustained-release Tablets Sales (2021-2032)
  5. 2.2.3 Global Mirabegron Sustained-release Tablets Market Average Price (2021-2032)
  6. 2.3 Mirabegron Sustained-release Tablets by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 25mg per Tablet
  9. 2.3.3 50mg per Tablet
  10. 2.4 Mirabegron Sustained-release Tablets by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital and Clinic
  13. 2.4.3 Pharmacy
  14. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Mirabegron Sustained-release Tablets Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Mirabegron Sustained-release Tablets Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Mirabegron Sustained-release Tablets Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Mirabegron Sustained-release Tablets Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Mirabegron Sustained-release Tablets Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Mirabegron Sustained-release Tablets, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Mirabegron Sustained-release Tablets, Product Type & Application
  8. 3.8 Global Manufacturers of Mirabegron Sustained-release Tablets, Established Date
  9. 3.9 Global Mirabegron Sustained-release Tablets Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Alkem Laboratories
  2. 4.1.1 Alkem Laboratories Company Information
  3. 4.1.2 Alkem Laboratories Business Overview
  4. 4.1.3 Alkem Laboratories Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Alkem Laboratories Mirabegron Sustained-release Tablets Product Portfolio
  6. 4.1.5 Alkem Laboratories Recent Developments
  7. 4.2 Astellas Pharma
  8. 4.2.1 Astellas Pharma Company Information
  9. 4.2.2 Astellas Pharma Business Overview
  10. 4.2.3 Astellas Pharma Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Astellas Pharma Mirabegron Sustained-release Tablets Product Portfolio
  12. 4.2.5 Astellas Pharma Recent Developments
  13. 4.3 Lupin Pharmaceuticals
  14. 4.3.1 Lupin Pharmaceuticals Company Information
  15. 4.3.2 Lupin Pharmaceuticals Business Overview
  16. 4.3.3 Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio
  18. 4.3.5 Lupin Pharmaceuticals Recent Developments
  19. 4.4 Zydus Lifesciences
  20. 4.4.1 Zydus Lifesciences Company Information
  21. 4.4.2 Zydus Lifesciences Business Overview
  22. 4.4.3 Zydus Lifesciences Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Zydus Lifesciences Mirabegron Sustained-release Tablets Product Portfolio
  24. 4.4.5 Zydus Lifesciences Recent Developments
  25. 4.5 China Resources Pharmaceutical
  26. 4.5.1 China Resources Pharmaceutical Company Information
  27. 4.5.2 China Resources Pharmaceutical Business Overview
  28. 4.5.3 China Resources Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 China Resources Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  30. 4.5.5 China Resources Pharmaceutical Recent Developments
  31. 4.6 Jiangsu Huayang Pharmaceutical
  32. 4.6.1 Jiangsu Huayang Pharmaceutical Company Information
  33. 4.6.2 Jiangsu Huayang Pharmaceutical Business Overview
  34. 4.6.3 Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  36. 4.6.5 Jiangsu Huayang Pharmaceutical Recent Developments
  37. 4.7 Jiangxi Shanxiang Pharmaceutical
  38. 4.7.1 Jiangxi Shanxiang Pharmaceutical Company Information
  39. 4.7.2 Jiangxi Shanxiang Pharmaceutical Business Overview
  40. 4.7.3 Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  42. 4.7.5 Jiangxi Shanxiang Pharmaceutical Recent Developments
  43. 4.8 Qilu Pharmaceutical
  44. 4.8.1 Qilu Pharmaceutical Company Information
  45. 4.8.2 Qilu Pharmaceutical Business Overview
  46. 4.8.3 Qilu Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Qilu Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  48. 4.8.5 Qilu Pharmaceutical Recent Developments
  49. 4.9 Shenzhen Main Luck Pharmaceuticals
  50. 4.9.1 Shenzhen Main Luck Pharmaceuticals Company Information
  51. 4.9.2 Shenzhen Main Luck Pharmaceuticals Business Overview
  52. 4.9.3 Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio
  54. 4.9.5 Shenzhen Main Luck Pharmaceuticals Recent Developments
  55. 4.10 CSPC Pharmaceutical
  56. 4.10.1 CSPC Pharmaceutical Company Information
  57. 4.10.2 CSPC Pharmaceutical Business Overview
  58. 4.10.3 CSPC Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 CSPC Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  60. 4.10.5 CSPC Pharmaceutical Recent Developments
  61. 4.11 Sichuan Gowell Pharmaceutical
  62. 4.11.1 Sichuan Gowell Pharmaceutical Company Information
  63. 4.11.2 Sichuan Gowell Pharmaceutical Business Overview
  64. 4.11.3 Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  66. 4.11.5 Sichuan Gowell Pharmaceutical Recent Developments
  67. 4.12 Zhejiang Huayi Pharmaceutical
  68. 4.12.1 Zhejiang Huayi Pharmaceutical Company Information
  69. 4.12.2 Zhejiang Huayi Pharmaceutical Business Overview
  70. 4.12.3 Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  72. 4.12.5 Zhejiang Huayi Pharmaceutical Recent Developments
  73. 4.13 Chia Tai Tianqing Pharmaceutical
  74. 4.13.1 Chia Tai Tianqing Pharmaceutical Company Information
  75. 4.13.2 Chia Tai Tianqing Pharmaceutical Business Overview
  76. 4.13.3 Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  78. 4.13.5 Chia Tai Tianqing Pharmaceutical Recent Developments
5 Global Mirabegron Sustained-release Tablets Market Scenario by Region
  1. 5.1 Global Mirabegron Sustained-release Tablets Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Mirabegron Sustained-release Tablets Sales by Region: 2021-2032
  3. 5.2.1 Global Mirabegron Sustained-release Tablets Sales by Region: 2021-2026
  4. 5.2.2 Global Mirabegron Sustained-release Tablets Sales by Region: 2027-2032
  5. 5.3 Global Mirabegron Sustained-release Tablets Revenue by Region: 2021-2032
  6. 5.3.1 Global Mirabegron Sustained-release Tablets Revenue by Region: 2021-2026
  7. 5.3.2 Global Mirabegron Sustained-release Tablets Revenue by Region: 2027-2032
  8. 5.4 North America Mirabegron Sustained-release Tablets Market Facts & Figures by Country
  9. 5.4.1 North America Mirabegron Sustained-release Tablets Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Mirabegron Sustained-release Tablets Sales by Country (2021-2032)
  11. 5.4.3 North America Mirabegron Sustained-release Tablets Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Mirabegron Sustained-release Tablets Market Facts & Figures by Country
  16. 5.5.1 Europe Mirabegron Sustained-release Tablets Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Mirabegron Sustained-release Tablets Sales by Country (2021-2032)
  18. 5.5.3 Europe Mirabegron Sustained-release Tablets Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Mirabegron Sustained-release Tablets Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Mirabegron Sustained-release Tablets Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Mirabegron Sustained-release Tablets Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Mirabegron Sustained-release Tablets Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Mirabegron Sustained-release Tablets Market Facts & Figures by Country
  41. 5.7.1 South America Mirabegron Sustained-release Tablets Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Mirabegron Sustained-release Tablets Sales by Country (2021-2032)
  43. 5.7.3 South America Mirabegron Sustained-release Tablets Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Mirabegron Sustained-release Tablets Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Mirabegron Sustained-release Tablets Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Mirabegron Sustained-release Tablets Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Mirabegron Sustained-release Tablets Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Mirabegron Sustained-release Tablets Sales by Type (2021-2032)
  2. 6.1.1 Global Mirabegron Sustained-release Tablets Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Mirabegron Sustained-release Tablets Sales Market Share by Type (2021-2032)
  4. 6.2 Global Mirabegron Sustained-release Tablets Revenue by Type (2021-2032)
  5. 6.2.1 Global Mirabegron Sustained-release Tablets Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Mirabegron Sustained-release Tablets Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Mirabegron Sustained-release Tablets Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Mirabegron Sustained-release Tablets Sales by Application (2021-2032)
  2. 7.1.1 Global Mirabegron Sustained-release Tablets Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Mirabegron Sustained-release Tablets Sales Market Share by Application (2021-2032)
  4. 7.2 Global Mirabegron Sustained-release Tablets Revenue by Application (2021-2032)
  5. 7.2.1 Global Mirabegron Sustained-release Tablets Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Mirabegron Sustained-release Tablets Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Mirabegron Sustained-release Tablets Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Mirabegron Sustained-release Tablets Value Chain Analysis
  2. 8.1.1 Mirabegron Sustained-release Tablets Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Mirabegron Sustained-release Tablets Production Mode & Process
  5. 8.2 Mirabegron Sustained-release Tablets Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Mirabegron Sustained-release Tablets Distributors
  8. 8.2.3 Mirabegron Sustained-release Tablets Customers
9 Global Mirabegron Sustained-release Tablets Analyzing Market Dynamics
  1. 9.1 Mirabegron Sustained-release Tablets Industry Trends
  2. 9.2 Mirabegron Sustained-release Tablets Industry Drivers
  3. 9.3 Mirabegron Sustained-release Tablets Industry Opportunities and Challenges
  4. 9.4 Mirabegron Sustained-release Tablets Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst